OncoPharm
OncoPharm
John Bossaer
P1: Tamoxifen for Breast Cancer Risk Reduction
16 minutes Posted Oct 11, 2018 at 7:30 pm.
0:00
16:06
Download MP3
Show notes
The Landmarks in Oncology Pharmacy series returns with the P1 study. We review this landmark paper paving the way for breast cancer risk reduction (or chemoprevention) and discuss the mark or lack thereof (frown emoji) it has made in clinical practice.